BMO Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $511. The stock dropped over ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE